The U.S. Department of Justice announced the emergency scheduling of three opioid compounds under Schedule I of the Controlled Substances Act due to public safety risks. Mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16 are classified as potent mu-opioid receptor agonists linked to dependence and respiratory depression. The Drug Enforcement Administration temporarily placed these substances in Schedule I to regulate their manufacture, distribution, and possession. Attorney General Todd Blanche emphasized the need to address emerging threats from manufactured opioid products. The order allows federal authorities to enforce controls against these compounds but excludes incidental trace levels of MGPI in botanical kratom products, provided they meet regulatory criteria. This action does not alter the scheduling status of other substances or restrict FDA authority.
Source: U.S. Department of Justice (DOJ).
Materials reproduced from https://www.justice.gov/.
No endorsement by the DOJ is implied.
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.